Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Initiates Coverage On Blend Labs with Outperform Rating

William Blair analyst Bhavan Suri initiates coverage on Blend Labs (NYSE:BLND) with a Outperform rating.

byBenzinga Newsdesk

August 10, 2021

1 minute read

William Blair analyst Bhavan Suri initiates coverage on Blend Labs (NYSE:BLND) with a Outperform rating.

JP Morgan Maintains Neutral on Douglas Emmett, Lowers Price Target to $32

By Benzinga Newsdesk

Today, 5:08 AM

JP Morgan analyst Anthony Paolone maintains Douglas Emmett (NYSE:DEI) with a Neutral and lowers the price target from $38 to $32.

DEI

Sage Therapeutics – Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

By Vandana Singh

Today, 5:08 AM

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing

BIIB

Credit Suisse Maintains Neutral on Hess, Raises Price Target to $150

By Benzinga Newsdesk

Today, 5:08 AM

Credit Suisse analyst William Janela maintains Hess (NYSE:HES) with a Neutral and raises the price target from $125 to $150.

HES

Why Hibbett Shares Are Sliding Today

By Shivani Kumaresan

Today, 5:08 AM

Hibbett Inc (NASDAQ:HIBB) reported a first-quarter FY22 revenue decline of 16.3% year-over-year to $424.1 million, missing the consensus of $427.66…

HIBB

William Blair Initiates Coverage On Blend Labs with Outperform Rating

Related Posts

JP Morgan Maintains Neutral on Douglas Emmett, Lowers Price Target to $32

Sage Therapeutics – Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

Credit Suisse Maintains Neutral on Hess, Raises Price Target to $150

Why Hibbett Shares Are Sliding Today